Johnson & Johnson reported positive Phase 3 results for ICOTYDE (icotrokinra), a targeted oral peptide that blocks the IL-23 receptor, in biologic-naïve adults with active psoriatic arthritis (PsA). In the ICONIC-PsA 1 study, 58% of patients receiving ICOTYDE 200 mg achieved an ACR20 response at Week 16, compared with 41% on placebo. ACR50 and ACR70 responses were 29% and 13%, respectively, versus 16% and 5% for placebo. Among patients with qualifying skin involvement, 57% achieved clear or almost clear skin and 37% reached PASI 90, compared with 14% and 6% on placebo. By Week 24, response rates had risen numerically to 69% for ACR20, 40% for ACR50 and 18% for ACR70, while 64% achieved clear or almost clear skin and 56% reached PASI 90. Safety data through Week 24 were consistent with ICOTYDE’s established profile, with no new safety signals. The findings were presented as a late-breaking poster at the American College of Rheumatology Convergence 2026. ICOTYDE is approved in the United States for moderate-to-severe plaque psoriasis but is not approved for active PsA.